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Abstract
The Kenzan bioprinting method provides a high-resolution biofabrication process by facilitating 
the fusion of submillimeter cell aggregates (spheroids) into larger tissue constructs on a needle 
array that is removed upon spheroid fusion. Although the method is relatively straightforward in 
principle, Kenzan method bioprinting relies on a complex 3D bioprinter (Regenova Bio 3D 
Printer, Cyfuse, K.K., Japan) implementing an advanced vision system to verify the microscopic 
spheroids’ geometry and high-precision mechatronics to aseptically manipulate the spheroids into 
position. Due to the complexity of the operation, the need for aseptic conditions, and the size of 
the spheroids, proficiency with the Regenova Bio 3D Printer and the Kenzan method requires 
development of best practices and troubleshooting techniques to ensure a robust print and 
minimize the use of resources. In addition, managing the construct post-bioprinting both in culture 
and for surgical implantation requires careful consideration and workflow design. Here, we 
describe methods for generating a competent tissue construct and optimizing the bioprinting 
process. Optimization resulted in a 4-fold reduction in print times, a 20-fold reduction in the use of 
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bioprinting nozzles, and more robust constructs. The results and procedures described herein will 
have potential applications for tissue engineering, research, and clinical uses in the future.
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Introduction
The Kenzan bioprinting method provides the highest resolution biofabrication method 
available in the known literature. With this method, 500 μm cellular spheroids can be placed 
in close proximity to one another such that they fuse into a larger tissue construct123. 
Spheroids can be made with homogenous or heterogenous cell populations and any spheroid 
combination can be printed onto the Kenzan array (figure 1((a), (b) and (c)). The Kenzan 
array is an array of stainless steel needles, 10 mm in length and 170 μm in diameter, spaced 
400 μm apart in either a 9×9 or a 26×26 pattern. Kenzan Bioprinting occurs on the Regenova 
Bio 3D Printer (Cyfuse, K.K., Japan; figure 2) which relies on a camera-based machine 
vision system, plate handling platform (not shown), disposal chamber (not shown), a 
container holding a Kenzan needle array submerged in PBS, and a nozzle connected to a 
pressure system on a 6 axis gantry. During the printing process, a spheroid is first located 
and inspected by the vision system. Next, the spheroid is picked up from the culture plate 
with suction from the nozzle, “skewered” onto a needle on the Kenzan array, and placed on 
the needle according to a preprogrammed 3D pattern. Therefore, tissue constructs can be 
printed with diverse cell populations in anatomically correct structural scales found in 
natural tissues. For example, channels can be generated either at the scale of the needle 
diameters (~200 μm) or by omitting spheroids from a particular location in the array. Despite 
the relative simplicity of Kenzan method biofabrication, proficiency with the Regenova 
requires development of best practices and troubleshooting to minimize operator error, 
optimize print time, reduce cost of use, and ensure a robust print. In addition, maturation of 
the bioprinted construct and its transfer from the culture environment to the surgical site 
must be carefully considered so as to avoid damaging the construct or introducing 
contaminants. Here we describe practical methods for streamlining the Kenzan 
biofabrication workflow with the Regenova, troubleshooting tips, and post-bioprinting topics 
necessary for generating a competent tissue construct which could eventually be implanted. 
Bioprinting has several applications in tissue replacement and regeneration, including bone 
repair. Therefore, this study was performed in the context of regenerating bone in a calvarial 
defect model immortalized bone marrow stromal cells (BMSCs) that were differentiated to 
the osteogenic lineage.
Methods
Bone marrow derived stromal cell (BMSC) culture
Immortalized BMSCs were originally isolated from C57BL/6 mice which were alkaline 
phosphatase positive and could mineralize4. BMSCs were expanded and cultured in control 
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medium. Control medium was composed of: Alpha-Minimum Essential Medium (α-MEM, 
Gibco ®, NY, USA), 10% fetal bovine serum (Atlas Biologicals, CO, USA), 1% penicillin-
streptomycin-glutamate (Gibco ®, NY, USA), and 0.001% amphotericin B (Sigma-Aldrich, 
MO,USA). Cells were cultured until they were approximately 90% confluent and were 
seeded into new dishes for the generation of spheroids as detailed below.
Spheroid formation
BMSC passage number 24-37 were seeded at 20,000 or 40,000 cells/well in ultra-low 
attachment (ULA) U-bottom 96 well plates (SBIO™, Japan). The BMSCs collected at the 
bottom of the well either under the force of gravity or under centrifugation for 5 min at 
300G, forming spheroids. BMSC spheroids were cultured in control medium for three days 
prior to printing.
3D Bioprinting
We attempted 4 separate “Trials” of printing constructs using the Kenzan biofabrication 
method and the Regenova Bio 3D Printer. Throughout the remainder of the manuscript, 
specific experimental conditions will be described in reference to sequential trial number 
(e.g. Trial 1, Trial 2, Trial 3, or Trial 4).
Prior to printing, a 5 mm diameter construct with a total of 324 spheroids in 2 layers (~800 
μm thick) for Trial 1 (not shown) or with a total of 648 spheroids in 4 layers (~1600 μm 
thick) for Trials 2-4 (figure 3(a)) was designed using the Bio 3D Designer software provided 
with the Regenova Bio 3D Printer. To set up each print, the container containing a 26×26 
needle Kenzan in PBS, the reservoir system (which is used to transfer negative pressure 
during spheroid pickup), and the nozzles were autoclaved separately, allowed to cool, and 
installed aseptically into the printer (figure 2 and 3(b)). The pressure system can be 
autoclaved with a nozzle installed onto it, although there is a risk of damage to the needle 
during handling. To begin a bioprint, the vision system first scans the needle array to ensure 
the needles are not bent or missing and can be visualized by the vision system. The vision 
system then scans the nozzle for straightness, nozzle diameter, and to calibrate nozzle 
location. If these elements are within specification, the plate handler will remove a 96- well 
plate from the plate magazine and place it into the printing position where the vision system 
identifies a spheroid within a well and quantifies spheroid parameters (distance from the 
well center, diameter, roundness, and smoothness (figure 3(c)). The roundness is determined 
by measuring the radius of the smallest circumscribed circle of the spheroid (R) and the 
radius (r) of an inscribed circle, concentric with the first circle, and contacting the spheroid 
perimeter. Roundness is then calculated using equation (1):
Roundness[ % ] = 100 − (R − r)R ∗ 100 (1)
Smoothness percentage is calculated by measuring the area of the regions deviating from the 
average of the minimum and maximum contour areas of the spheroid (DA) and then dividing 
DA by the spheroid area (SA):
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Smoothness[ % ] = DASA ∗ 100 (2)
Spheroid specifications can be set by the user, and for all trials were 450-550 μm diameter, 
76-100 % roundness, and 0-10.0% smoothness.
If the spheroid is within specification, the gantry will lower the nozzle into the well and 
exert low negative pressure, suctioning the ~500 μm spheroid onto the tip of the 26 gauge 
nozzle (figure 3(d)). The nozzle then moves away from the well and the vision system scans 
the well for the spheroid. If the spheroid is no longer observed by the vision system, the 
spheroid is presumed to be on the nozzle and the nozzle will then move into position over 
the needle array, lower itself onto a preselected needle (using position control), impaling the 
spheroid onto the needle (figures 3(d) and (e)). The pressure on the nozzle is then released, 
releasing the spheroid which stays in position. If a spheroid is observed in the well by the 
vision system after an attempted pickup, this is considered a failed pickup and the system 
will try to pick up the spheroid as many times as determined by the user. Once the 
preselected number of pickup attempts has passed, the system will stop and inform the 
operator. Upon spheroid placement the system will move to the next spheroid, in the next 
well, and will continue the printing process until the construct is completed. Construct 
bioprinting progression is observed by the machine vision system (figures 3(f), (g), and (h)) 
and can be observed directly from the side of the Kenzan container (figure 3(i)).
Nozzle installation—Nozzles used for manipulating spheroids during printing must be 
sterile. The manufacture’s nozzle installation procedure calls for securing the first nozzle to 
the reservoir system prior to autoclaving. For subsequent needle changes, the manufacturer 
calls for securing the nozzle onto the reservoir system using forceps. This awkward grip and 
hand motion required for nozzle installation resulted in dropped nozzles which would result 
in nozzle damage and would potentially damage the printer, and specifically, the vision 
system which is housed, in part, under the nozzle. The manufacturer’s method also added 
considerable time to the printer setup time. To mitigate nozzle installation issues, each 
nozzle was sheathed with a 1000 μL pipette tip. These sheathed needles could be autoclaved 
and gripped by the pipette tip such that each nozzle could be aseptically installed using a 
gloved hand and finger tightened (Supplemental video 1).
Failed nozzle scans after component exchanges—When plates or Kenzan needle 
arrays were being exchanged in the middle of a print, some fluid remained on the nozzle tip. 
When the vision system scanned the nozzle at printing restart, fluid was registered as part of 
the nozzle, resulting in the nozzle being out of specification. To mitigate this issue in Trials 3 
and 4 a sterile Pasteur pipette was manually touched to the nozzle, which draws the fluid 
away from the fluid away from the nozzle by electrostatic force. Once the fluid was removed 
from the tip, the nozzle scanned with no errors. The fluid could also be allowed to dry so 
that nozzle diameter was back in specification but this would lengthen the print time 
considerably.
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Thresholds and blind pickups—The Regenova vision system allows the user to adjust 
the thresholds for spheroid distance from the well center, diameter, percent smoothness, and 
percent roundness. While these are used to indicate that the spheroids are within a 
preselected specification, cellular debris and matrix secreted from the spheroid during 
maturation can be registered by the Regenova. As an example, cellular and secreted 
extracellular matrix debris from spheroids can take on a round form with a diameter smaller 
than that of the spheroid. When the nozzle picks up a spheroid and the vision system checks 
the well again for spheroid presence and registers the debris as a spheroid, the system will 
attempt to pick up the debris despite a spheroid already being held by the nozzle. These 
“blind pickups” can result in the loss of the picked up spheroid and a delay in printing. To 
mitigate these errors, the diameter threshold was adjusted to within 50 μm of the minimum 
spheroid diameter. For example, the spheroids utilized in this study had a minimum viable 
spheroid diameter of 450 μm. Therefore, the spheroid presence threshold was set to 400 μm.
Failed spheroid pickups—Despite the use of low-binding plates, possible poor coverage 
of the low-binding surface in the well bottom and possible scraping of this surface with 
pipette tips during culture may result in the spheroids adhering to the wells strongly enough 
that the nozzle cannot pick them up. In other cases, the nozzle pressure ruptures the spheroid 
such that part of the spheroid is drawn into the nozzle or the spheroid is ruptured in a way 
that the entire spheroid is drawn into the nozzle. Both scenarios can block the nozzle. 
Originally, the plates were lightly tapped to loosen them (Trial 1, Table 1). However, 
vigorous motion while tapping the plates spilled medium onto the lids, which increased risk 
of contamination without fully loosening all spheroids. Medium leakage onto the lid also 
causes a vacuum between the plate and lid which prevented the Regenova from removing the 
lid from the plate during the printing process, potentially damaging the machine. Therefore, 
to avoid failed pickups, spheroid rupture, and medium leakage, each spheroid was loosened 
by hand-pipetting 50 μl of medium in each well containing a spheroid several times with a 
micropipette just prior to printing. This flushing procedure loosened the spheroids so they 
could be easily picked up.
When weak or ruptured spheroids or other cellular debris are caught in the nozzle, 
generating a blockage and preventing spheroid pickup, the Regenova’s disposal feature is 
utilized to remove blockages. The disposal routine involves the nozzle moving into position 
over a small waste container with the nozzle tip being placed through the container opening. 
Air is forced through the nozzle at up to ~10 kPa. During the procedure, the digital nozzle 
pressure gauge should be observed. If the gauge reads ~4 to 7 kPa after a disposal step, the 
blockage has been cleared and printing can resume. If the gauge reads “FFF”, the pressure 
has exceeded the range of the reservoir system failsafe and the blockage is not clear. If, after 
several disposal routines, the gauge continues to read “FFF” and the blockage remains, the 
nozzle should be replaced.
If the spheroids are loosened and the disposal routine does not show an increase in pressure, 
there may be a loose connection in the nozzle reservoir system. The connections along the 
pressure line should be checked and reconnected and then a print step attempted.
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Maturation time—After printing, Trial 1 constructs with Kenzans were placed in a 
Magenta GA-7 Vessel (Carolina® Biological Supply Company, NC, USA) with control 
medium for one week. Medium was replaced 2 times/week. During medium changes, half of 
the medium was removed from the vessel, and an equivalent amount of fresh medium was 
added to the vessel. After one week of maturation, the constructs were carefully removed 
from the Kenzans by using forceps to grip the platen supporting the bottom of the construct 
and sliding the platen along the needles and off of the Kenzan, taking the construct with it 
(figure 1(a)). The constructs were separated from the platen and placed in a petri dish for 
two weeks in control medium. Half medium changes were continued on alternating days for 
an additional two weeks.
For Trial 2, constructs loaded on Kenzans were placed in a Magenta GA-7 Vessel for two 
weeks. One construct was placed in control medium. The second construct was placed in the 
same medium but supplemented with 200 mM β-glycerophosphate disodium salt hydrate 
(BGP) (Sigma-Aldrich, MO, USA) and 50 mg/ml of L-ascorbic acid 2-phosphate (AA) 
(Sigma-Aldrich, MO, USA), referred to as osteogenic medium. Half medium changes were 
completed twice a week. After 2 weeks in the containers, the constructs were carefully 
removed from the Kenzan with forceps using the methods described in Trial 1. They were 
placed in different Petri dishes that were previously coated with 2% agarose to prevent cell 
adhesion to the dish. Half medium changes were continued on alternating days for an 
additional week.
Trial 3 constructs with Kenzans were placed in a Magenta GA-7 Vessel for three weeks. 
Osteogenic medium was added to one construct on day 0 (Construct 1); osteogenic medium 
was added to the second construct on day 3 (Construct 2). Maturation time on the Kenzan 
within the vessel for both constructs was three weeks. Medium was changed twice a week 
(half medium changes). After 3 weeks, constructs were removed from the Kenzan and 
placed in a 2% agarose coated petri dish.
Trial 4 constructs with Kenzans were placed in a Magenta GA-7 Vessel for 3 weeks. 
Osteogenic medium was added to three constructs on day 3; osteogenic medium was added 
to the other three constructs on day 7. Osteogenic medium was changed twice a week (half 
medium changes). After 3 weeks, constructs were removed from the Kenzan. This was 
accomplished by using sterile gloves and forceps to aseptically slide the top platen (figure 
1(a)) from the needle array such that the construct remained on the platen. The back-side of 
a surgical spatula was then used to slide the construct from the platen (figure 3(j) and (k)).
Results
Sheathing nozzles with pipette tips reduced the number of dropped and damaged nozzles 
considerably, though the number of nozzles lost during bioprinter installation was not 
recorded. Loosening the spheroids prior to printing led to a reduction in failed pickups and 
in blockages leading to nozzle changes. In Trial 1, an average of 65 spheroids were printed 
per hour. Loosening the spheroids with the pipettes increased the print rate to 87-93 
spheroids per hour in Trials 2 and 3. This also reduced the number of nozzle changes.
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In Trial 3, the additional step of cleaning fluid from the nozzle contributed to further 
reducing the printing time. However, light reflecting from the spheroids interfered with the 
machine vision and image processing such that the needle position could not be resolved for 
spheroid placement. Therefore, manual spheroid placement was employed for Trial 3, 
contributing to a print time which was only slightly decreased compared to Trial 2. Lighting 
adjustments made prior to Trial 4 reduced the need for manual spheroid placement. As 
detailed in Table 1, reducing failed pickups, the number of nozzle changes, and cleaning the 
nozzle contributed to a 20-fold decrease in the number of nozzles used (nozzles are single 
use), and print rate of spheroids increased by a factor of four from 65 spheroids per hour 
(Trial 1) to 260 spheroids per hour (Trial 4).
For Trials 1 and 2, the constructs were removed from the Kenzans 1 to 2 weeks after 
printing. The constructs did not have much structural rigidity and folded over on themselves 
and became misshapen in the week following removal from the Kenzan. Since the Kenzan 
needles provide structural support, Trial 3 constructs were removed from the Kenzans three 
weeks after printing (figure 4(a) and (b)) and were subjected to osteogenic medium 
beginning at 0 or 3 days post-bioprinting. The 0-day constructs almost completely 
disintegrated at the spheroid level during handling following Kenzan removal (figure 4(a) 
and 4(c)) while 3-day constructs broke into large pieces and also showed some spheroid-
level disintegration (figure 4(b), 4(d) and 5(a-c)). Histology of tissue fragments confirmed 
high cellularity in both constructs (figure 4 (e) and (f)).
To determine the influence of the media on spheroid fusion, Trial 4 constructs were 
transitioned from control medium to osteogenic medium after 3 or 7 days. The 7-day 
constructs, compared to the 3-day constructs, could be handled without disintegrating 
(figures 3(j), 3(k) and 5(d-f)) , suggesting that constructs should be kept on the Kenzan 
needle array and in control medium (as opposed to osteogenic medium) long enough for 
spheroids to fuse to one another prior to differentiation and ECM deposition. Moreover, the 
7-day constructs were robust enough to withstand handling while the 3-day constructs had to 
be scooped from the Kenzan platen to avoid construct damage (figure 5(f)). Also of note 
were the microchannels left in Trial 4 constructs by the Kenzan needles.
Discussion
Over the course of our investigations and biofabrication projects, we have learned several 
best practices that can significantly improve bioprinting efficiency and bioprinted construct 
quality while also reducing bioprinting waste and costs. Here we summarize our findings. 
While the culture plates used to culture spheroids have been treated to reduce cell adhesion, 
ULA coverage on the well surface is not ideal and may be prone to removal by scratches 
from pipette tips during cell seeding and medium exchange. It is also possible that the ultra-
low adhesion coating was not as effective as intended. Therefore, a spheroid loosening 
procedure was employed to release the spheroids from the well floor. Additionally, high 
spheroid adhesion had an adverse effect on spheroid pick up, resulting in spheroids being 
ruptured and portions of the ruptured spheroids being drawn into the nozzle, causing a 
blockage. Blockages cause costly delays in printing time and increase costs due to the need 
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for nozzle replacement. In some cases, ruptured or partial spheroids are placed onto the 
Kenzan, undermining the final print.
The constructs are bioprinted on a Kenzan submerged in PBS since culture media 
supplemented with serum may interfere with the Regenova’s machine vision system. Since 
the PBS has no nutrients, keeping the constructs in PBS long term, as printing issues (i.e., 
repeated failed pickups, repeated disposal routines to clear nozzle blockages, repeated 
nozzle replacements, and thresholding) are resolved, can compromise cell viability and alter 
cell differentiation or metabolism, confounding print results. Increased printing time, 
particularly in events that require manually manipulating Regenova components, exposes the 
constructs to risk of contamination. The Regenova is fitted with a sash, a HEPA filter, and 
negative air pressure to reduce the chance for contaminants to enter the build envelope. 
However, risk of contamination increases with the number of times elements near the 
Kenzan are manipulated and the number of times the Regenova’s sash is opened.
Constructs freshly printed in the Regenova are extremely fragile, requiring best practices in 
work flow to prevent damage prior to implantation. The first step to reducing construct 
damage is to ensure that spheroids within the construct are adequately fused prior to 
handling for culture or implantation. In initial Trials, constructs were subjected to osteogenic 
medium 0 or 3 days post-bioprinting. The 0-day constructs almost completely disintegrated 
at the spheroid level during handling following Kenzan removal (figure 4(a) and 4(c)) while 
3-day constructs broke into large pieces and also showed some spheroid-level disintegration 
(figure 4(b) and 4(d)). Poor fusion suggests that secretion of extracellular matrix (ECM) 
induced by osteogenic medium may have prevented cell-cell adhesion between spheroids, or 
that differentiation altered cell-cell adhesions. Previous studies have demonstrated this 
phenomenon, concluding that more mature spheroids, defined as having increased ECM, 
result in slower spheroid fusion5. To generate competent tissues, it is critically important to 
appreciate that fusion behavior is different for different cell populations. Thus, spheroid 
fusion behavior must be properly characterized and optimized for each cell type so that 
procedural, timing, and biochemical regimens can be developed to achieve robust bioprinted 
tissues. Since ECM concentration is shown to regulate spheroid fusion5, controlling ECM 
deposition rate, which can also be described as speeding-up or slowing-down maturation, 
may result in better control of spheroid fusion, and thus, tissue integrity. For example, 
Mironov et al. demonstrated that fibrillogenic agents such as transforming growth factor beta 
1 (TGFβ1) increased spheroid cohesion, which reduced the spheroid’s ability integrate with 
other spheroids.1 As a result, spheroids produced without fibrillogenic agents, which 
accordingly had lower ECM concentrations, placed adjacent to TGFβ1-matured spheroids 
were able to envelop the more mature spheroids. Therefore, biochemical methods for 
slowing down spheroid maturation should be explored to enhance spheroid maturation. Once 
the spheroids are adequately fused, fibrillogenic biochemical agents can be applied to 
enhance integrity of the bioprinted tissue. On the other hand, ECM deposition for some cell 
types may be low or slow enough that spheroids fuse quickly but do not possess the 
mechanical integrity to remain intact post-bioprint. In these cases, it may be necessary to 
provide fibrillogenic agents to rapidly increase post-bioprint construct strength. With regard 
to generating complex tissues, further characterization and nuanced post-bioprinting 
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maturation regimens must be accomplished for heterospheroidal bioprints to account for 
differences in spheroid maturation and thus interspheroid fusion1,5.
Therefore, a separate set of constructs (Trial 4) were exposed to osteogenic medium 3 or 7 
days after post-printing. The 7-day constructs, compared to the 3-day constructs, could be 
handled without disintegrating (figures 3(j) and 3(k)), suggesting that differentiation and 
ECM deposition can significantly affect spheroid fusion. Construct culture immediately after 
printing may need to be optimized for cell-cell interaction, adhesion, and spheroid fusion. 
Handling the fragile constructs may also lead to damage. Initial Trials involved construct 
transfer from the Kenzan array to an intermediate culture chamber during post-printing 
maturation. These constructs not only began to fall apart, but extra handling put them at risk 
for contamination. Keeping the constructs on the Kenzan until just before implantation 
would reduce the number of times and the degree to which the construct is handled, limiting 
potential damage to the constructs.
Keeping the construct on the Kenzan until just before implantation could be beneficial with 
the microchannels left by the Kenzan needles. While the Kenzan method was originally 
intended for these microchannels to close during long-term culture67, maintaining them 
would provide Haversian canal-like channels through which nutrients can interact with the 
interior of the construct. These microchannels are most visible in figure 4(d). Ongoing 
studies are investigating methods for maintaining the patency and direct perfusion of these 
Haversiancanal-like channels to enhance nutrient delivery during long-term culture.
Properly clearing fluid droplets from the nozzle and loosening the spheroids to ensure 
complete pickup reduced the number of nozzle failures/changes which considerably reduced 
the printing time (Table 1). The bioprint for Trial 1 resulted in 2 constructs (2 layers each) 
on the same Kenzan. Trial 1 therefore printed at an average rate of 65 spheroids per hour 
which increased to 260 spheroids per hour in Trial 4. With increasing demand for use of the 
Regenova, the cost of consumable components, and bioprinting facility charges for using the 
bioprinter, the reduction in printing time and reduced use of resources as a result of 
streamlining the bioprinting technique will allow greater user access, ensure reproducibility, 
reduce the risk of contamination and cell death, reduce operating costs, and increase 
Regenova output.
Conclusion
The Kenzan method of biofabricating constructs generated on the Regenova represents an 
advance in biofabrication due to the system’s ability to generate dimensionally-accurate 
scaffold-free tissue constructs with submillimeter resolution and the ability to place 
individual cell populations (spheroids) adjacent to one another, approximating the apposition 
of diverse populations in complex tissues. Generating tissue construct models exhibiting cell 
populations heterogeneity modeled after natural tissue compositions can provide valuable 
information about cell-cell interactions and lead to effective therapies8. Therefore, spheroid-
based bioprinting has applications in tissue engineering, studying tissue development and 
tissue disease models, and, potential clinical uses1. However, operating the Regenova 
proficiently requires development of best practices to ensure quality prints since operating 
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the machine without streamlining the bioprinting workflow can quickly become 
prohibitively expensive. The constructs generated may also be fragile and prone to 
contamination, meaning careful consideration of the post-bioprinting and implantation 
workflow are required to ensure that Kenzan method bioprints are competent for in vivo use. 
Continuing to advance bioprinting and post-bioprinting techniques with the Kenzan method 
and the Regenova will lead to research discoveries in tissue engineering, improved tissue 
models for development and disease research, and clinical applications where robust, high 
resolution, scaffold-free biofabrication is desired. An additional level of sophistication is to 
perfuse the constructs using a perfusion bioreactor such as the FABRICA bioreactor 
platform to ensure that the constructs are receiving adequate nutrition9.
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Figure 1: Kenzan Method Biofabrication.
(a) The Kenzan needle array is comprised of several needles arrayed in a 9×9 or a 26×26 
pattern. A 26×26 Kenzan is shown in this image. Spheroids are impaled onto the Kenzan 
needles such that spheroids contact one another and fuse. Fused spheroids form a tissue 
construct. Tissue constructs can be removed by sliding the top platen from the bottom 
platen, keeping the construct intact. (b) Image of three spheroids on a Kenzan needle just 
after printing. (c) Image of fused spheroids on a Kenzan needle a day after printing. Needle 
diameters are 200 μm.
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Figure 2: Regenova Biofabrication Components
Primary components of the Regenova Bio 3D Printer include camera and lighting 
components as part of the machine vision system, a pressure gauge to determine pressure 
applied to the spheroids as they are picked up, a nozzle connected to the reservoir system 
and the pressure gauge, and container holding the Kenzan needle array.
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Figure 3: Bioprinting Preparation, Progression, and Construct Integrity.
(a)The construct is designed using “Bio 3D Designer”, software provided by the Regenova 
manufacturer. (b) The bioprinting components are installed into the bioprinter. The nozzle 
on the far left and the reservoir system bottle on the far right are used to aspirate each 
spheroid on to the nozzle. (c) The machine vision system inspects each spheroid for 
location, diameter in micrometers, roundness, and smoothness based on thresholds specified 
by the user. (d) Once a spheroid passes inspection, it is aspirated lightly onto the nozzle tip 
using the pressure system. (e) The nozzle, which is mounted onto a 6-axis gantry, is then 
placed over the Kenzan needle array and placed onto a preselected needle at the height 
corresponding with the construct design set forth using Bio 3D Designer. (f,g, and h) 
Bioprint progress is observed after each spheroid placement using the Regenova machine 
vision system. (i) Construct progression can also be observed manually from the side of the 
Kenzan container. (j and k) For Trial 4, the constructs were removed from Kenzans after 3 
weeks to minimize handling and avoid construct disintegration.
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Figure 4: Trial 3 Construct Outcomes Following Osteogenic Differentiation 0 and 3 Days After 
Bioprinting.
(a and c) Constructs treated with osteogenic differentiation medium immediately following 
bioprinting disintegrated upon Kenzan removal, even after 2 weeks of culture on the Kenzan. 
(b and d) Constructs treated with differentiation medium 3 days after bioprinting, cultured 
on-Kenzan for 2 weeks, and then cultured off-Kenzan for 1 week showed increased integrity, 
yet still showed construct breakage and spheroid-level disintegration. Continued culture off-
Kenzan resulted in a warped and misshapen construct that did not maintain original 
dimensions. Micropores left by the Kenzan needles are also visible. These pores provide 
Haversian canallike microchannels through which nutrients can be transported to the interior 
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of the construct. (e) Hematoxylin and eosin stain from tissue fragments of construct 1. (f) 
Hematoxylin and eosin stain from tissue fragments of construct 2.
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Figure 5: Trial 3 and 4 Constructs Outcomes
(a through c) Trial 3 constructs resulted in constructs with poorly-fused spheroids. (d 
through f) Trial 4 constructs maintained integrity and could withstand handling.
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